Full-Time

Regional Sales Associate

Endoscopy

Stryker

Stryker

10,001+ employees

Manufactures orthopedic and surgical medical devices

Compensation Overview

$85k/yr

+ Commission + Bonus

Company Historically Provides H1B Sponsorship

Nashville, TN, USA

In Person

The role is field-based and requires frequent travel, including up to 90% overnight travel annually.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Sales
GMP
CRM
Marketing
Customer Service
OSHA

Get referred to Stryker

See people who can refer or advise you

Requirements
  • The candidate must have 1-2 years of experience in an outside sales position; experience in medical-related fields is preferable.
  • A Bachelor of Arts or Bachelor of Science degree is required.
  • The candidate must complete field sales training, the in-house product training program, and computer training.
  • The candidate must be able to handle routine overnight travel on short notice for extended periods, with up to 90% overnight travel annually.
  • The candidate must be able to exert up to 50 pounds of force occasionally and up to 20 pounds constantly to move objects.
  • The candidate must be able to communicate with large groups of people and communicate telephonically.
  • The candidate must be able to use common office equipment and drive an automobile.
  • The candidate must be able to negotiate transaction prices and terms between the company and its customers.
  • The candidate must be able to resolve customer complaints and questions and provide customer service.
  • The candidate must understand all products, including their functionality, features, and differentiators from competitors’ products, and communicate this knowledge to customers.
  • The candidate must be able to analyze territory market potential and prioritize call patterns accordingly.
  • The candidate must follow operating room and pertinent Occupational Safety and Health Administration guidelines during product evaluations.
  • The candidate must adhere to Good Manufacturing Practice policies and procedures stipulated by the Food and Drug Administration.
Responsibilities
  • Assist Sales Representatives in marketing, promoting, and selling company products when not covering employee leaves of absence or other business coverage needs.
  • Market, promote, and sell company products and maintain strong, positive customer relationships while covering employee leaves of absence or other business coverage needs.
  • Travel, often on short notice and sometimes for extended periods, to perform sales tasks in multiple territories and provide business coverage.
  • Educate and inform doctors, nurses, and appropriate staff about the proper use and maintenance of products, product functionality and updates, portfolio changes, and educational programs.
  • Tailor the company’s promotional message based on customer knowledge, advise on product selection, answer customer questions about product functionality, and distinguish company products from competitors’ products.
  • Direct product evaluations in operating room and office settings.
  • Assist with the preparation and operation of trade shows, conventions, and clinical meetings.
  • Keep the regional manager informed of territory progress regularly.
  • Resolve product problems for customers promptly.
  • Manage and maintain a sample inventory of products.
Desired Qualifications
  • Experience in medical-related outside sales is preferable.

Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kalamazoo, Michigan

Founded

1941

Get referred to Stryker

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 organic sales rose 9%, with strong MedSurg and Orthopaedics growth.
  • AVS closed in Q2 2026, expanding peripheral vascular exposure and salesforce leverage.
  • Management raised 2026 outlook to 8.3%-9.3% organic growth and $14.95-$15.10 EPS.

What critics are saying

  • March 2026 cyberattack disrupted manufacturing, delayed shipments, and exposed operational fragility.
  • Peripheral vascular supply disruption created Q2 2026 backorders, with recovery targeted only by Q3.
  • Any repeat cyber incident or plant outage would hit revenue and threaten 2026 guidance.

What makes Stryker unique

  • Mako robotics keeps winning installations and supports Stryker's orthopedic workflow lock-in.
  • Stryker spans MedSurg, Neurotechnology, and Orthopaedics, cushioning demand across procedure types.
  • Pangea Plating and TPX HD show a steady, surgeon-led product launch cadence.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical & prescription plans

Supplemental health benefits

Flexible Spending accounts

Employee Assistance Program

Short-term & long-term disability

Tuition reimbursement

401(k) plan

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 2nd, 2026
Stryker shares drop 6.4% after Q2 earnings as analysts see 23% upside to $386.80 fair value

Stryker shares fell 6.42% following its second-quarter 2026 earnings release, which showed sales of $6.59 billion and net income of $1.28 billion. The medical technology company is now trading approximately 23% below one valuation estimate and 18% beneath the average analyst target. Analysts currently place Stryker's fair value at $386.80, compared to its recent closing price of $325.70. Price targets vary significantly amongst analysts, ranging from $315 to $465. The year-to-date share price return has fallen 6.46%, though the company maintains a five-year total shareholder return of 30.66%. Potential risks to the company's outlook include prolonged EU regulatory delays and sustained supply chain disruptions that could affect product launches and margins.

Yahoo Finance
Aug 1st, 2026
Stryker meets Q2 revenue expectations at $6.59B but supply chain woes dampen growth outlook

Stryker reported Q2 revenue of $6.59 billion, up 9.4% year on year, meeting Wall Street expectations. The medical technology company's non-GAAP earnings of $3.69 per share beat analyst estimates by 5.8%. Despite meeting forecasts, investors reacted negatively due to supply chain disruptions in the peripheral vascular business. Chief executive Kevin Lobo said the quarter focused on recovery from a recent cybersecurity incident, which caused production disruptions and elevated backlogs. The company expects backorders to normalise by the end of Q3. Management cited strong demand for capital equipment and Mako robotics, which saw record Q2 installations. Operating margin expanded to 25.2% from 18.5% last year, supported by operational discipline and efficiency initiatives. Management slightly raised full-year adjusted earnings guidance.

Yahoo Finance
Jul 31st, 2026
Stryker reports 9% organic sales growth in Q2 2026 despite cybersecurity impact

Stryker reported strong second-quarter 2026 results with 9% organic sales growth, driven by high single-digit gains in both its med surg and neurotechnology and orthopaedics businesses. The medical device company is recovering from a cybersecurity incident whilst ramping up production to meet demand. In the US, Stryker achieved 9% organic sales growth, with double-digit expansion in its medical, trauma extremities, and endoscopy divisions. The company's OrthoTech and instruments segments posted high single-digit growth. However, supply disruptions affected the peripheral vascular business, creating a significant backorder situation and lost sales. Stryker expects to resolve these issues by the end of the third quarter. The company also completed its acquisition of AVS during the quarter and remains confident in the long-term outlook for its peripheral vascular business.

Yahoo Finance
Jul 30th, 2026
Stryker reports $6.6B Q2 sales, up 9.4%, as company recovers from cyber incident

Stryker Corporation reported second quarter 2026 results, with net sales rising 9.4% to $6.6 billion and organic sales up 9.0%. The medical technology company's adjusted earnings per share increased 17.9% to $3.69, whilst reported EPS jumped 44.1% to $3.30. The company's MedSurg and Neurotechnology division posted sales of $3.6 billion, up 9.7%, with organic growth of 9.2%. Orthopaedics sales reached $3.0 billion, increasing 9.1%. Chair and CEO Kevin Lobo attributed the strong performance to recovery from a cyber incident, noting the company's resilience. Adjusted operating margin improved 170 basis points to 27.4%. Stryker expressed confidence in maintaining growth at the high end of the medical technology sector for the second half of 2026.

Yahoo Finance
Jul 1st, 2026
Stryker's joint-replacement moat edges Intuitive's premium valuation despite Q1 cyberattack

Stryker reported $6.02 billion in revenue for Q1 2026, missing the $6.33 billion consensus following a March cyberattack, whilst Intuitive Surgical beat expectations with $2.77 billion in revenue, up 23%, and earnings per share of $2.50 against a $2.11 consensus. Despite the cyberattack impact, Stryker's core businesses remained strong, with its Mako-driven orthopaedics franchise growing and its Vascular division jumping 27.5% following the Inari acquisition. The company maintained full-year guidance of 8% to 9.5% organic growth and delivered free cash flow of $415 million, up 227%. Stryker trades at approximately 22 times forward earnings compared to Intuitive Surgical's 39 times, as da Vinci procedure growth guidance steps down from 18% to roughly 15%.